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liver toxicity in patients co-infected with HIV and HCV with advanced liver fibrosis in Taiwan.
Methods: This retrospective cohort study included 228 HAART-experienced and HAART-naı¨ve
patients who were co-infected with HIV and HCV from January 2013 to December 2013 in
Taiwan. Transaminase elevation (TE) was defined by grades. Fibrosis 4 score and aspartate-
to-platelet ratio index were used to evaluate liver fibrosis. Cox proportional hazard regression
model was used to analyze the risk factors for time to TE events.
Results: A total of 228 patients were included. Only two episodes (1.28%) of high-grade TE
were observed. The overall prevalence rate of TE was 16%, and the incidence was 1.38
cases/100 patient-months. Two predictive factors of TE were the initiation of HAART during
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HAART-related hepatitis in HIV and HCV 547HAART improved liver fibrosis status in patients who had advanced liver fibrosis at baseline
(p Z 0.033).
Conclusion: The frequency of HAART-related TE in HIV and HCV co-infected patients in Taiwan
was much lower than that observed in previous studies. Pre-existing advanced liver fibrosis had
no influence on the frequency of TE. The use of HAART showed benefits on liver fibrosis pro-
gression in patients with underlying advanced liver fibrosis.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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Co-infection with hepatitis virus is a common condition in
patients infected with human immunodeficiency virus
(HIV). Hepatitis C virus (HCV), in particular, has become a
major concern because of its high prevalence, especially in
patients with intravenous drug use, and its association with
higher morality and liver-related morbidities in HIV-
infected patients.1e3 With the introduction of highly
active antiretroviral therapy (HAART), HIV-related mortal-
ity and the risk of opportunistic infections had greatly
decreased. However, an increasing amount of research has
been focused on the issue of HAART-related liver injury,
especially in patients infected with both HIV and HCV.4e7
Because they share the same route of infection, HCV co-
infection with HIV is most commonly seen in patients with
intravenous drug use. Compared to the prevalence of HCV
in HIV-infected patients with intravenous drug use in
Europe (75e82%), the prevalence in Taiwan (96.6%) and
China (95.1e99.3%) is much higher,1,8e11 which makes the
management of HIV/HCV co-infection and the surveillance
of HAART safety regarding liver injury more important in
these regions. Several articles have discussed the impact of
different HAART combinations on liver injury in those co-
infected with HIV and HCV in Europe and the United
States. HAART-related hepatotoxic events, such as high-
grade (Grades III and IV) transaminase elevation (TE),
acute liver failure, and death have been reported.4e7,12
However, no relevant data reporting the incidence of
HAART-related hepatotoxicity are available in Taiwan. In
addition, co-infection with HIV and HCV also causes a more
rapid progression of liver fibrosis,13 and the status of liver
fibrosis and the effect on HAART-related liver injury in this
population in Taiwan are also unknown.
The aim of this study, therefore, was to evaluate the
frequency of HAART-related liver injury and the effect of
different HAART regimens in patients co-infected with HIV
and HCV in Taiwan, a high-prevalence area. The status of
advanced liver fibrosis was also assessed and the impact on
HAART-induced liver injury was analyzed.
Patients and methods
Study design and patients
This study was a retrospective cohort study including
HAART-experienced and HAART-naı¨ve HIV-infected patients
who were regularly followed up at a special outpatient
clinic for intravenous drug users of a tertiary teachinghospital in southern Taiwan from January 1, 2013 to
December 31, 2013. Patients with HIV and HCV co-infection
were included. All of the patients were treated in accor-
dance with the Taiwan Guidelines for Diagnosis and Treat-
ment of HIV/AIDS at the time of prescription. The choice of
HAART regimen was made by clinical physicians. All pa-
tients who experienced HAART during the study period
received HAART for at least 1 week. Clinical and laboratory
examinations were carried out at baseline, after the first 4
weeks, and every 4e6 months thereafter until the end of
the study. No patients in this study received additional
antiviral regimens other than HAART. The primary end point
was the occurrence of TE. The study end date was
December 31, 2013, if no TE was observed; otherwise, the
date when TE level was found was used.
Definition of TE and other laboratory investigations
Baseline levels of plasma aspartate aminotransferase (AST)
and alanine aminotransferase (ALT) were measured. In the
patients with normal baseline levels of AST and ALT, values
of AST and ALT 1.25e2.5 times the upper level of normality
(ULN) were considered to have Grade I TE, 2.6e5 times the
ULN were considered to have Grade II TE, and more than
five times the ULN were considered to have high-grade TE
(Grades III and IV). In the patients who presented with
abnormal baseline levels of AST and ALT, a 1.25e2-fold
increase from baseline was considered Grade I TE, a 2.5e5-
fold increase as Grade II TE, and a more than 5-fold in-
crease as high-grade TE (Grades III and IV).
The diagnosis of hepatitis B virus (HBV) infection was
based on the positive result of HBV surface antigen radio-
immunoassay. HCV infection was diagnosed based on the
presence of serum HCV antibody, determined by anti-HCV
enzyme-linked immunosorbent assays kit (ARCHITECT
i1000SR, Abbott Laboratories). Plasma HIV viral load was
measured using COBAS AMPLICOR HIV-1 monitor test,
version 1.5 (Roche Diagnostics Corporation, Indianapolis,
IN, USA). Undetectable viral load was defined as plasma HIV
viral load less than 50 copies/mL. CD4 lymphocyte sub-
populations were quantified by FACSFlow (Becton Dickinson
and Company, Franklin Lakes, NJ, USA).
Assessment of liver fibrosis
Two noninvasive models, namely, fibrosis 4 score (FIB-4)
and aspartate-to-platelet ratio index (APRI), were used to
evaluate the status of liver fibrosis. FIB-4 was calculated by
age, AST level, ALT level, and platelet count, and a value
548 C.-C. Chou et al.greater than 3.25 was considered indicative of advanced
liver fibrosis.14,15 The APRI was derived from the AST level
and platelet count, and a result of 1.5 or more was
considered positive for advanced liver fibrosis.16 Both these
models had been proven to have high specificity and posi-
tive predictive value in diagnosing advanced liver fibrosis in
HIV/HCV co-infected patients.14,17,18 In this study, the
diagnosis of advanced liver fibrosis was established if either
of these two models was positive for advanced liver fibrosis.
Baseline AST level, ALT level, and complete blood count
were obtained for model calculations when the patients
entered the study.
Statistical analysis
The outcome variable was the development of TE during
follow up. The relationships between the outcome variable
and the following potential predictors were assessed: age,
sex, baseline CD4 cell count, undetectable plasma HIV
load, baseline AST and ALT levels, advanced liver fibrosis,
and HAART use (including the following 3 groups: not on
HAART during the study period, already on HAART on study
entry, and initiating HAART after study entry).
Continuous variables were expressed as median and
interquartile range (IQR), and categorical variables as
number (percentage, 95% confidence interval). Continuous
variables were compared using the Student t test or Man-
neWhitney U test. Categorical variables were analyzed by
the Chi-square test or Fisher’s test, when applicable. A p
value less than 0.05 was considered statistically significant.
Cox proportional hazard regression model was used to
analyze the risk factors for developing TE. Covariates with p
value of 0.1 or less on univariate analyses were entered into
the multivariate model using the forward selection method.
Patients were followed up until they developed TE, or were
censored on December 31, 2013. Data were analyzed using
Stata 10.0 (StataCorp LP, College Station, TX, USA).
Ethics statement
Institutional Review Board approval was obtained from the
Commission on Medical Ethics of the Kaohsiung Veterans
General Hospital (VGHKS14-CT4-14) and the patient data
were delinked.
Results
Characteristics of the study population
In total, 336 HIV-infected patients had regular follow up in
the special outpatient clinic. Two hundred and twenty-
eight patients with HCV co-infection were included in this
study, with a median follow-up period of 252 (IQR,
222e301) days. All of these 228 patients were found to be
former intravenous drug users. Two hundred and fifteen
patients had data available for the assessment of baseline
advanced liver fibrosis, and 149 of these 215 patients had
data available for the assessment of advanced liver fibrosis
at the end of the study. Complete laboratory examination
results to evaluate TE were available for 156 patients. Thecharacteristics of patients with TE, including the existence
of advanced liver fibrosis at baseline and use of HAART, are
shown in Fig. 1. The main baseline features of the study
population are presented in Table 1. The median (IQR) time
of follow up was 257 days (range, 222e301 days) in patients
without advanced liver fibrosis and 243 days (range,
222e286 days) in patients with advanced liver fibrosis
(p Z 0.216). Patients were classified into three groups ac-
cording to the use of HAART, as shown in Fig. 1: initiated
HAART after study entry (new use), already on HAART at
study entry (existing use), and never on HAART during the
study period (no use). In patients without baseline liver
fibrosis (n Z 169), 19 (11.2%) initiated HAART after study
entry, with 17 (10.1%) patients using non-nucleoside
reverse transcriptase inhibitors (NNRTIs) and two (1.2%)
patients using protease inhibitors (PIs). Thirty-six patients
(21.3%) had already been on HAART on study entry, of which
28 (16.6%) patients were using NNRTIs and eight (4.7%) were
using PIs. In patients with baseline advanced liver fibrosis
(n Z 46), 11 (23.9%) patients initiated HAART after study
entry, of which eight (17.4%) used NNRTIs, two (4.3%) used
PIs, and one (2.2%) used integrase inhibitor; five (10.9%)
patients had already been on HAART at study entry, with
four (8.7%) on NNRTIs and one (2.2%) on PIs.Liver events
None of study individuals died or hospitalized for liver-
related events during the study period. A total of 156 pa-
tients underwent complete biochemistry examinations
allowing for the assessment of TE. TE occurred in 25 (16%)
patients. The incidence rate was 1.38 cases/100 patients-
months (95% confidence interval, 0.92e2.05).The predictors
of the occurrence of TE are shown in Table 2. New use of
HAART [odds ratio (OR), 3.88; 95% confidence interval,
1.41e10.76] and CD4 count less than 350 cells/mm3 (OR,
4.13; 95% confidence interval, 1.46e11.65) were the inde-
pendent predictors of TE. The hazard ratio (HR) of new use
of HAART compared with no use of HAART and the HR of
count less than 350 cells/mm3 compared with CD4 count of
350 cells/mm3 or more were 5.11 (95% confidence interval,
2.08e12.59; p < 0.001) and 3.79 (95% confidence interval,
1.42e10.10; p Z 0.003), respectively. The adjusted HR of
these two factors was 3.93 (95% confidence interval,
1.55e9.95; p Z 0.004) and 2.87 (95% confidence interval,
1.04e7.7.94; p Z 0.042), respectively (Table 3). Age, sex,
undetectable viral load, baseline AST/ALT level, and
advanced liver fibrosis were not found to be associated with
a higher number of TE episodes in HIV/HCV co-infected
patients. In all patients with occurrence of TE, only two
(1.3%) patients had high-grade TE, both of whom had Grade
IV TE. Both patients did not receive HAART. In 32 patients
who initiated HAART after study entry, 10 (31.3%) episodes
of TE were observed, and there were six (15.8%) episodes of
TE in 38 patients who had been on HAART at study entry, as
compared with nine (10.5%) of 86 patients who had never
been on HAART during the study period. All 10 episodes of TE
in patients who initiated HAART after study entry were not
high-grade TE. Six of them were Grade I TE and four of them
were Grade II TE. Likewise, five of six episodes of TE in
patients who had been on HAART at study entry were Grade
Table 1 Baseline characteristics of the study population
Without advanced liver
fibrosis (n Z 169)
With advanced liver
fibrosis (n Z 46)
p
Male, n (%) 132 (78.1) 41 (89.1) 0.095
Age (y), median (Q1eQ3) 39 (31e45) 43 (38e47) 0.006
IDU, n (%) 169 (100) 46 (100)
CD4, n (%) >500 37 (21.9) 5 (10.9) 0.2
350e500 47 (27.8) 11 (23.9)
200e350 75 (44.4) 25 (54.4)
<200 10 (5.9) 5 (10.9)
Undetectable VL, n (%)a 33 (19.6) 3 (6.52) 0.035
HBV, n (%)b 27 (16.2) 7 (15.6) 0.92
Baseline AST (IU/mL),
median (Q1eQ3)
28 (21e40) 75.5 (38e117) <0.001
Baseline ALT (IU/mL),
median (Q1eQ3)
35 (24e59) 81 (41e182) <0.001
HAARTc New use 19 (11.2) 11 (23.9) 0.053
Existing use 36 (21.3) 5 (10.9)
No use 114 (67.5) 30 (65.2)
a Data of HIV viral load test were available in 214 patients. Undetectable viral load was defined as serum HIV viral load < 50 copies/mL.
b Data of HBV serum surface antigen test were available in 212 patients.
c New use: initiating HAART after study entry; existing use: already on HAART on study entry; no use: never on HAART during the study
period.
ALT Z alanine transaminase; AST Z aspartate transaminase; HAART Z highly active antiretroviral therapy; HBV Z hepatitis B virus;
HIV Z human immunodeficiency virus; IDU Z intravenous drug use; VL Z viral load.
Figure 1. Characteristics of patients with transaminase elevation (TE). A total of 336 patients were enrolled in the study, and 228
of them were included. Patients were categorized by existence of advanced liver fibrosis and use of highly active antiretroviral
therapy (HAART)dinitiated HAART after study entry (new use), already on HAART at study entry (existing use), and never on HAART
during study period (no use). Numbers (percentage) of patients with TE as outcome variable were shown in each category.
HCV Z hepatitis C virus; HIV Z human immunodeficiency virus.
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Table 2 Predictors of transaminase elevation (N Z 156)
N TE, n (%) p
Age
>40 y 64 11 (17.2) 0.74
40 y 92 14 (15.2)
Sex
Male 117 19 (16.2) 0.9
Female 39 6 (15.4)
Baseline CD4 cell counta
<350 cells/mm3 84 20 (23.8) 0.005
350 cells/mm3 71 5 (7)
Baseline viral load
50 copies/mL 122 19 (15.6) 0.771
<50 copies/mL 34 6 (17.7)
Baseline AST levelb
Abnormal 57 10 (17.5) 0.695
Normal 99 15 (15.2)
Baseline ALT levelb
Abnormal 73 13 (17.8) 0.569
Normal 83 12 (14.5)
Advanced fibrosis
Yes 29 3 (10.3) 0.412
No 127 22 (17.3)
HAART usec
New use 32 10 (31.3) 0.024
Existing use 38 6 (15.8)
No use 86 9 (10.5)
New use of HAART
NNRTI 27 8 (29.6) 0.709
PI 4 2 (50)
II 1 0 (50)
a Data of CD4 count were available in 155 patients.
b AST upper limit of normal range: 35 U/L; ALT upper limit of
normal range: 40 U/L.
c New use: initiating HAART after study entry; existing use:
already on HAART on study entry; no use: never on HAART
during the study period.
ALT Z alanine aminotransferase; AST Z aspartate amino-
transferase; HAART Z highly active antiretroviral therapy;
II Z integrase inhibitor; NNRTI Z non-nucleoside reverse-
transcriptase inhibitor; PI Z protease inhibitor;
TE Z transaminase elevation.
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time (IQR) to onset of TE in patients who initiated HAART
after study entry was 52.5 days (range, 42e124 days) and
183.5 days (range, 140e246 days) in patients who had
already been on HAART at study entry (p Z 0.008). In pa-
tients with baseline CD4 cell count of 350 cells/mm3 or more
who developed TE, none had ever used HAART during the
study period. By contrast, 16 (80%) of 20 patients who had a
baseline CD4 cell count of less than 350 cells/mm3 and
developed TE used HAART during the study period. Ten of
them (50%) initiated HAARTafter study entry and six (30%) of
them had been on HAART at study entry (pZ 0.002).
Influence of pre-existing advanced liver fibrosis
In the overall population, three (10.3%) of the 29 patients
with advanced liver fibrosis had TE, whereas 22 (17.3%) ofthe 127 patients without advanced liver fibrosis had TE
(p Z 0.412). In the patients initiating HAART after study
entry, TE occurred in two (20%) patients with underlying
advanced liver fibrosis and in eight (44.4%) without under-
lying advanced liver fibrosis (p Z 0.247), whereas in the
patients already on HAART at study entry, TE occurred in
one (20%) patient with underlying advanced liver fibrosis
and in five (14.7%) without underlying advanced liver
fibrosis (p Z 1; Fig. 1).
Influence of HAART on advanced liver fibrosis
In the 215 patients with data available for assessment of
baseline liver fibrosis status, 149 patients had AST, ALT, and
platelet count examination for assessment of liver fibrosis
status at the end of study. Based on changes in the liver
fibrosis status between the study entry and the end of the
study, patients were classified into the following two sub-
groups: the improved group, in which advanced liver
fibrosis was found at the study entry but not found at the
end of study, and the not-improved group, in which the
status of liver fibrosis did not change or even became
worse. Eleven patients were classified into the improved
group and 138 patients were classified into the not-
improved group. For the improved group, eight patients
used HAART during the study period, of which five (45.5%)
patients initiated HAART after study entry and three
(27.3%) patients had been already on HAART at study entry,
whereas in the not-improved group, 23 (16.7%) patients
initiated HAART after study entry and 32 (23.2%) patients
had already been on HAART at study entry (p Z 0.033).
More patients received HAART in the improved group than
in the nonimproved group.
Discussion
The results of this study showed that drug-induced liver
injury associated with HAART was uncommon in patients
with HIV/HCV co-infection with and without advanced liver
fibrosis. Subgroup analysis showed a trend of liver fibrosis
regression in patients with underlying advanced liver
fibrosis after receiving HAART. In addition, no significant
influence of preexisting advanced liver fibrosis on the
development of TE was observed.
The frequency of HAART-related high-grade liver toxicity
has been evaluated in several previous cohort studies. In
four cohort studies analyzing the side effects of different
HAART combinations including efavirenz, nevirapine, and
boosted PI in HIV and HCV co-infected patients, the prev-
alence of high-grade (Grades III and IV) TE was 6e25%.19e22
Our study, in which all patients were HIV and HCV co-
infected, found no episode of high-grade TE in those who
received HAART. None of the patients stopped anti-HIV
treatment because of the tolerable low-grade TE. The
difference in prevalence may be due to different HCV ge-
notypes in different geographic regions. Most HCV geno-
types in Taiwan were genotypes six and one in intravenous
drug users with or without HIV infection,9,23 whereas the
main HCV genotypes in other cohort studies in Western
countries were genotypes one, three, and four.19e22
Another possible explanation might be the short follow-up
Table 3 Hazard ratios for the development of transaminase elevation
HR 95% CI p Adjusted HR 95% CI p
Age
>40 y 1.05 0.47e2.30 0.913
40 y
Sex
Male 0.92 0.36e2.32 0.855
Femaleg
Baseline CD4 cell counta
<350 cells/mm3 3.79 1.42e10.10 0.003 2.87 1.04e7.94 0.042
350 cells/mm3
Baseline viral load
50 copies/mL 0.82 0.33e2.07 0.678
<50 copies/mL
Baseline AST levelb
Abnormal 1.12 0.50e2.49 0.79
Normal
Baseline ALT levelb
Abnormal 1.20 0.55e2.64 0.647
Normal
Advanced fibrosisc
Yes 0.52 0.15e1.73 0.284
No
HAART used
New use 5.11e 2.08e12.59 <0.001 3.93 1.55e9.95 0.004
Existing use 1.87f 0.66e5.28 0.239 1.44 0.50e4.19 0.498
No use
a Data of CD4 count were available in 155 patients.
b AST upper limit of normal range: 35 U/L; ALT upper limit of normal range: 40 U/L.
c Assessment of liver fibrosis was available in 150 patients.
d New use: initiating HAART after study entry; existing use: already on HAART on study entry; no use: never on HAART during the study
period.
e HR of new use of HAART compared with no use of HAART.
f HR of existing use of HAART compared with no use of HAART.
g Covariates with p value of 0.1 or less on univariate analyses were entered into the multivariate model using the forward selection
method.
ALT Z alanine aminotransferase; AST Z aspartate aminotransferase; CI Z confidence interval; HAART Z highly active antiretroviral
therapy; HR Z hazard ratio.
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later in the treatment course. Although the initiation of
HAART was one of the independent risk factors for the
development of TE, the low and nonsignificant hepatic side
effects suggested that HAARTwas safe for patients with HIV
and HCV co-infection. Many mechanisms have been pro-
posed to explain this phenomenon in hepatitis virus and HIV
co-infected patients, including direct drug toxicity, im-
mune response to HAART against hepatitis virus antigen,
hypersensitivity reactions with liver involvement, and
mitochondrial toxicity.24 Because of the different targets of
each drug in HAART, further studies with regard to the
specific mechanism of drug-related hepatotoxicity from
certain drugs are required to elucidate this issue. By
contrast, HAART was found to reduce long-term liver-
related mortality and to have a beneficial impact on liver
fibrosis progression in HIV and HCV co-infected
patients.25e27 The long-term benefits of HAART should
outweigh the potential risks of hepatotoxicity.
A lower initial CD4 cell count was associated with a
higher rate of TE in both univariate and multivariateanalyses in a Cox proportional hazard regression model. In
all the patients with a CD4 cell count less than 350 cells/
mm3, use of HAART was found to be related to TE devel-
opment. The association of an initial CD4 cell count and
nevirapine-related hepatotoxicity is controversial.28e31
However, similar results to our study regarding a higher
rate of TE with lower baseline CD4 cell count was previously
reported by Pineda et al22 in a cohort study, which included
189 HIV and HCV co-infected patients who received ataza-
navir/ritonavir. It is known that a lower CD4 count in HIV-
infected patients leads to a higher frequency of immune
reconstitution inflammatory syndrome.32 With HAART
intervention, an increase in CD4 cells can lead to a severe
intrahepatic immune response against HCV.7 In addition, a
lower CD4 cell count means a later stage in HIV infection.
Injury to the liver directly from HIV at a later stage of the
disease may account for the higher rate of TE. These hy-
potheses may explain the association between lower CD4
cell count and the higher incidence of TE.
The influence of advanced liver fibrosis on HAART-
related hepatotoxicity has been a subject of debate over
552 C.-C. Chou et al.the last few years. Studies conducted by Aranzabal et al20
and Mira et al33 found a correlation between a higher
incidence of HAART-associated TE and significant liver
fibrosis in patients co-infected with HIV and HCV. In our
study, pre-existing advanced liver fibrosis was not a pre-
dictor of TE in HIV and HCV co-infected patients, and was
not related to HAART-associated TE as well. Several other
studies also reported the same conclusion.19e22
Neukam et al19 and Pineda et al21,22 found no association
between underlying advanced liver fibrosis and occurrence
of TE in different HAART regimens, including NNRTI and
boosted PI. Prospective studies with longer follow-up pe-
riods and a larger population size should be conducted to
confirm the relationship between liver fibrosis and TE fre-
quency in HIV and HCV co-infected patients.
Patients co-infected with HIV and HCV have a higher
liver-related mortality and morbidity than those with a
single infection.3,13 The introduction of HAART has not only
reduced the risk of opportunistic infection, but has also
shown beneficial effects with regard to long-term outcomes
of liver-related mortality and morbidity. Qurishi et al found
that HAART is an independent predictor of liver-related
survival in HIV/HCV co-infected patients.25. Benhamou
et al26 and Bra¨u et al27 found that the chronic use of HAART
has a beneficial effect on liver fibrosis progression. Sub-
group analysis in this study found that intervention of
HAART would improve liver fibrosis status in patients who
had underlying advanced liver fibrosis. This implies that
HAART has a protective effect on liver-related morbidity
caused by HCV and HIV.
There are a number of limitations to this study that
should be highlighted. First, the study population was
defined as patients co-infected with HIV and HCV. The
findings of this study cannot be applied in patients with
HIV or HCV monoinfection. Second, no liver biopsies were
performed, and no fibroscan was available for liver fibrosis
survey. In addition, the application of the two noninvasive
models used in this study to evaluate liver fibrosis was not
validated in a Taiwanese population. However, the APRI
and FIB-4 have been proven to have high specificity and
positive predictive values on advanced liver fibrosis in
patients co-infected with HIV and HCV. The APRI score was
reported to have a specificity of 95.4e100% and a positive
predictive value of 96.6e100% with a cutoff value of 1.5 or
more, whereas the FIB-4 score had a specificity of 97% and
a positive predictive value of 65% with a cutoff value
greater than 3.25 in predicting significant liver fibrosis
(Batt and Ludwig scoring, F2e4) in HIV/HCV co-infected
patients.14,17,18 Noninvasive investigations reduce the
risks, such as bleeding, involved with a liver biopsy,
especially for patients with possible coagulation
dysfunction related to end-stage liver disease. The use of
a single method also contributes to a degree of consis-
tency in the results. In addition, the data needed to
calculate the APRI and FIB-4 are all common biochemical
values in clinical practice, making it easier to evaluate the
liver fibrosis status in all patients. Third, the small sample
size was another limitation in this study, especially in
some specific subgroups, which also made it difficult to
evaluate the effects of different HAART regimens.
Because of the decreasing numbers of intravenous drug
users in Taiwan, the patients followed in our specialoutpatient clinic for this population have also been
reduced. Therefore, the present result should be
confirmed in a cohort study with a larger sample size. In
baseline characteristic analysis, patients in the group with
advanced liver fibrosis had older median age (43 years,
IQR 38e47 years) when compared with those in the groups
without advanced liver fibrosis (39 years, IQR 31e45 years;
p Z 0.006). The longer HIV and HCV infection period may
account for the difference between the two groups;
however, the time of HIV infection was not available for
every patient in this study.
In summary, the frequency of HAART-related hepato-
toxicity in patients co-infected with HIV and HCV was low in
our cohort of Taiwanese patients, regardless of the exis-
tence of advanced liver fibrosis. All these hepatotoxic
events were not severe and had no clinical significance. A
low CD4 cell count was associated with a higher rate of liver
injury, especially in patients who used HAART. The use of
HAART has a protective effect on liver-related morbidity by
improving liver fibrosis status in HIV and HCV co-infected
patients with baseline advanced liver fibrosis. Prospective
studies focusing on the effects of HAART on hepatitis in HIV
and HCV co-infected patients are needed to confirm our
findings.
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